Across 352 European CTIS orphan-drug Phase III trials, CRO or specialist vendor support appears in 298 trials, equal to 84.7%. IQVIA is the most active named provider with 93 supported trials, followed by PPD / Thermo Fisher with 89 and ICON / PRA with 80. CRO need is strongest in multinational execution: 80 of 84 trials across 10 or more countries used CRO support, equal to 95.2%.
Named CRO or specialist-vendor support appears in 298 of 352 trials. IQVIA leads with 93 trial appearances, representing 26.4% of all included trials, followed by PPD / Thermo Fisher with 89 trials, or 25.3%, and ICON / PRA with 80 trials, or 22.7%. Because trials can list more than one CRO or vendor, provider shares are not additive.
| Provider | Trials | Share |
|---|---|---|
| IQVIA | 93 | 26.4% |
| PPD / Thermo Fisher | 89 | 25.3% |
| ICON / PRA | 80 | 22.7% |
| Medidata | 58 | 16.5% |
| Parexel | 57 | 16.2% |
| Signant Health / ERT | 47 | 13.4% |
| Suvoda | 43 | 12.2% |
| Syneos Health | 42 | 11.9% |
Rare disease Phase III outsourcing is concentrated around large global CROs and enabling vendors. IQVIA, PPD / Thermo Fisher, and ICON / PRA together appear in 262 trial-provider records, showing that Europe-wide rare disease delivery usually combines full-service CRO capacity with specialized eClinical, lab, imaging, and IRT vendors.
CRO support rises most clearly with geographic complexity. Trials running in 10 or more countries show CRO support in 80 of 84 cases, or 95.2%. The strongest site-count band is 16–50 sites, where 120 of 133 trials, or 90.2%, list CRO support. By planned sample size, the 51–150 patient band has the highest CRO-support rate at 115 of 131 trials, or 87.8%.
| Dimension | Highest CRO-support band | CRO use |
|---|---|---|
| Countries | 10+ countries | 80 / 84 · 95.2% |
| Sites | 16–50 sites | 120 / 133 · 90.2% |
| EU participants | 26–100 participants | 112 / 126 · 88.9% |
| Planned sample size | 51–150 patients | 115 / 131 · 87.8% |
The clearest trigger for CRO need is not only patient volume, but EU execution spread. Once rare disease trials cross 5 countries, CRO use rises to 90.2%, and at 10 or more countries it reaches 95.2%, making CTIS country coordination, site activation, monitoring, translation, and vendor management the main operational pressure points.
Neurology has the strongest CRO-support rate among large therapeutic-area clusters, with 50 of 54 trials supported, or 92.6%. Musculoskeletal follows with 22 of 24 trials, or 91.7%, while immunology has 38 of 42 trials supported, or 90.5%. At disease level, generalized myasthenia gravis shows 7 of 7 trials with CRO support, while myelofibrosis shows 5 of 5.
CRO demand is especially strong in neurologic, musculoskeletal, immunology, endocrine, and ultra-rare disease settings where small patient pools still require multi-country activation. Multiple myeloma has the largest disease count with 16 trials, but its 75.0% CRO-support rate is lower than smaller rare-disease clusters that reach 100.0%.
Central laboratory, bioanalysis, and biomarker testing is the dominant outsourced function, appearing in 266 of 352 trials, or 75.6%. Clinical operations, monitoring, and project management appear in 218 trials, or 61.9%. Regulatory, CTIS, and EU submission support appears in 150 trials, or 42.6%, making submission execution one of the major non-lab outsourcing categories.
Rare disease Phase III outsourcing is not primarily only full-service CRO delivery. The most common need is specialized infrastructure: central labs, biomarker testing, imaging review, eClinical systems, IRT/RTSM, drug logistics, and CTIS/EU submission support.
Across 352 trials, the median time from initial CTIS submission to first authorization is 74.5 days. At country level, 2,046 CTIS Part II country applications show a median processing time of 137.5 days. Italy, Spain, France, and Germany are the largest execution markets, each appearing in more than 240 trial-country records.
| Country | Trial-country records | Sites | Participants | Part II median |
|---|---|---|---|---|
| Italy | 253 | 1,572 | 8,319 | 214d |
| Spain | 249 | 1,434 | 6,017 | 190d |
| France | 246 | 1,644 | 7,960 | 178d |
| Germany | 241 | 1,258 | 7,268 | 169.5d |
| Poland | 165 | 621 | 3,215 | 113.5d |
EU submission burden is concentrated in the same markets that carry the largest site and participant load. Italy, France, Spain, and Germany together account for 5,908 listed sites and 29,564 planned participants across trial-country records, so CTIS Part II coordination and country-specific document handling are logical outsourcing targets.
Oligonucleotide trials show CRO support in 33 of 35 cases, or 94.3%, and gene therapy trials show support in 20 of 22 cases, or 90.9%. Small molecules are the largest modality group with 212 trials, with CRO support in 174, or 82.1%. Monoclonal antibodies show 91 supported trials out of 108, or 84.3%.
| Modality | Supported / total | CRO support |
|---|---|---|
| Oligonucleotide | 33 / 35 | 94.3% |
| Gene therapy | 20 / 22 | 90.9% |
| Monoclonal antibody | 91 / 108 | 84.3% |
| Peptide / protein / enzyme | 63 / 75 | 84.0% |
| Small molecule | 174 / 212 | 82.1% |
Advanced modalities add demand for specialized vendors beyond general monitoring. Oligonucleotide and gene therapy trials are smaller than small-molecule trials but have higher CRO-support rates, consistent with the need for specialist lab, logistics, safety, long-follow-up, and CTIS country-documentation workflows.
CRO means contract research organization or CTIS-listed specialist trial-service provider. CTIS means the Clinical Trials Information System used for EU clinical trial submission and authorization. IRT/RTSM means interactive response technology / randomization and trial supply management. eCOA/ePRO means electronic clinical outcome assessment / electronic patient-reported outcome. IMP means investigational medicinal product.